677 related articles for article (PubMed ID: 28510338)
21. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
22. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
23. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
24. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
25. PARP inhibitors for anticancer therapy.
Curtin N
Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Puentes LN; Lengyel-Zhand Z; Reilly SW; Mach RH
Mol Neurobiol; 2021 Aug; 58(8):3641-3652. PubMed ID: 33788167
[TBL] [Abstract][Full Text] [Related]
29. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.
Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS
Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940
[TBL] [Abstract][Full Text] [Related]
30. Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance.
Lovsund T; Mashayekhi F; Fitieh A; Stafford J; Ismail IH
Cells; 2023 Jul; 12(14):. PubMed ID: 37508568
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Chu YY; Yam C; Yamaguchi H; Hung MC
J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
[TBL] [Abstract][Full Text] [Related]
32. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
33. PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention.
Zhu X; Ma X; Hu Y
Curr Med Chem; 2016; 23(17):1756-74. PubMed ID: 25245372
[TBL] [Abstract][Full Text] [Related]
34. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
35. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
36. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
37. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS; Camacho CV; Kraus WL
Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
[TBL] [Abstract][Full Text] [Related]
38. Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
[TBL] [Abstract][Full Text] [Related]
39. A New Opportunity for "Old" Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism.
Iglesias P; Seoane M; Golán-Cancela I; Fraga M; Arce VM; Costoya JA
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240195
[TBL] [Abstract][Full Text] [Related]
40. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
